tradingkey.logo

Harrow jumps on predicting Q4 sales above estimate

ReutersMar 18, 2025 9:30 AM

Harrow HROW.O soars ~24% to $28.90 premarket

Eye-drug maker sees prelim Q4 sales in the $65 mln-$67 mln range; analysts' estimate stands at $58.4 mln, per data compiled by LSEG

Forecasts 2025 sales to be more than $280 mln, slightly below analysts' estimate of $281.2 mln

Expects its FDA-approved, high-profit branded products to be the main driver of growth this year

HROW gained ~181% in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI